Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adverum Biotechnlgs (NQ: ADVM )

0.8550 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.8550
Bid (Size) 0.6000 (2)
Ask (Size) 0.8800 (6)
Prev. Close 0.8550
Today's Range 0.8550 - 0.8550
52wk Range 0.7954 - 3.860
Shares Outstanding 98,125,866
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy
 
Via Benzinga
Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD
 
Via Benzinga

Performance

YTD
-56.15%
-56.15%
1 Month
-25.00%
-25.00%
3 Month
-36.19%
-36.19%
6 Month
-56.38%
-56.38%
1 Year
-75.00%
-75.00%

More News

Read More
3 Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
Via Benzinga
Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
Via Benzinga
Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
Via Benzinga
44 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Via Benzinga
Mid-Afternoon Market Update: Dow Drops 375 Points; Elmira Savings Bank Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
30 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
18 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety
Via Benzinga
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.